Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.


Biotechnology

Pharmaceutical

Therapeutics

Carbon Biosciences

Carbon Biosciences' headquarters in Lexington, MA, United States

Joel Schneider

Sebastian Aguirre Kozlouski, Ph.D.

Brian Collins

Keith Dewedoff

Steve Dipalma

Amy Lurier

Bev Davidson

Adrian Thrasher

Chen Schor

Jay Chiorini

David Steinberg

Derek Yoon

John F. Engelhardt

The Scientific and Research Team at Carbon Biosciences is responsible for advancing the company's gene therapy platform by conducting cutting-edge research on novel parvoviruses, optimizing gene delivery methods, and developing experimental models to target specific tissues. This team collaborates closely with translational biology and analytical development experts to innovate and refine therapeutic approaches, aiming to tackle some of the most challenging diseases with enhanced efficacy and safety profiles.

Scientific and Research Team

The Leadership Team at Carbon Biosciences drives the strategic vision and operational execution of the company's innovative gene therapy initiatives. Comprising experts in nonclinical development, manufacturing, and platform development, this team collaborates to advance the proprietary parvovirus platform, ensuring alignment with clinical goals, streamlining processes, and fostering partnerships to address challenging diseases. Their collective expertise shapes the direction of research, development, and commercialization efforts, positioning Carbon Biosciences at the forefront of gene therapy advancements.

Leadership Team

The Development Team at Carbon Biosciences is responsible for advancing the company's proprietary gene therapy platform. This includes designing and optimizing novel parvovirus-based vectors, conducting preclinical studies to assess efficacy and safety, and developing analytical methods to ensure product quality. The team works collaboratively to push the boundaries of gene therapy, targeting specific diseases with high unmet needs.

Development Team

This department oversees organizational leadership and strategic direction.

Executive Governance

The Process Development team at Carbon Biosciences focuses on creating and optimizing the manufacturing processes for their novel gene therapy products. This includes scaling up production, ensuring consistency and quality, and integrating cutting-edge technologies to enhance the efficiency and effectiveness of gene delivery. They collaborate closely with other departments to translate laboratory research into scalable, clinically viable therapies.

Process Development

This department manages the organization's financial planning, reporting, and investments.

��

Carbon Biosciences

Org chart

Board & advisors

Teams

Scientific and Research Team

Leadership Team

Development Team

Executive Governance

Process Development

Finance Department

Offices

��������

Carbon Biosciences

Org chart

Board & advisors

Teams

Scientific and Research Team

Leadership Team

Development Team

Executive Governance

Process Development

Finance Department

Offices

Related companies

��